Amneal Pharmaceuticals, Inc. (AMRX) KPIs and segments
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
KPIs & segments
Operating metrics and segments that drive Amneal Pharmaceuticals's business
Amneal Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Affordable Medicines($M)11 | 490 | 423 | 437 | 461 | 433 | 415 | 439 | 427 | 427 | 391 | 363 | 391 | |
Subtotal dosage forms($M) | 482 | 418 | 432 | 413 | |||||||||
United States($M) | 437 | 461 | 433 | 415 | 439 | 427 | 427 | 391 | |||||
Oral solid($M) | 175 | 171 | 178 | 179 | |||||||||
Other dosage forms($M) | 81.6 | 46.6 | 68.2 | 56.4 | |||||||||
Transdermal($M) | 67.0 | 74.0 | 40.7 | 43.1 | |||||||||
Auto-Injector($M) | 62.2 | 41.9 | 66.6 | 48.2 | |||||||||
Injectable($M) | 56.8 | 49.9 | 34.6 | 34.8 | |||||||||
Biosimilar($M) | 29.1 | 22.3 | 25.2 | 28.5 | |||||||||
Oral liquid($M) | 10.4 | 12.1 | 17.9 | 23.5 | |||||||||
International($M) | 7.61 | 5.32 | 1.90 | 1.23 | |||||||||
International and other($M) | 4.51 | 1.43 | 1.72 | 0.45 | 0.87 | ||||||||
AvKARE($M)4 | 157 | 166 | 211 | 199 | 163 | 172 | 170 | 159 | 170 | 163 | 149 | 132 | |
Distribution($M) | 86.9 | 89.1 | 99.7 | 105 | |||||||||
Government label($M) | 50.2 | 59.9 | 45.4 | 50.1 | |||||||||
Institutional($M) | 12.1 | 9.82 | 10.1 | 11.0 | |||||||||
Other($M) | 7.74 | 7.10 | 7.83 | 6.37 | |||||||||
Specialty($M)5 | 149 | 133 | 167 | 125 | 128 | 108 | 121 | 116 | 104 | 105 | 104 | 97.3 | |
Subtotal therapeutic classes($M) | 149 | 133 | 128 | 108 | |||||||||
Central nervous system($M) | 95.3 | 83.4 | 83.4 | 67.6 | |||||||||
Hormonal/Allergy($M) | 42.1 | 35.9 | 35.4 | 34.2 | |||||||||
Other therapeutic classes($M) | 11.9 | 14.0 | 8.70 | 6.49 | |||||||||
License agreement($M) | 0 | 0.50 | |||||||||||
Affordable Medicines($M) | 123 | 121 | 82.0 | 85.6 | 102 | 111 | 91.9 | 88.3 | 101 | -11.4 | 46.9 | 87.4 | |
Specialty($M) | 54.9 | 50.1 | 9.57 | 35.5 | 15.0 | 32.4 | 26.9 | 29.2 | 18.6 | ||||
AvKARE($M) | 9.34 | 22.4 | 25.5 | 27.0 | 18.1 | 12.9 | 7.46 | 13.1 | 11.0 | 11.3 | 9.12 | 11.9 | |
Affordable Medicines($M) | 207 | 191 | 151 | 180 | 181 | 172 | 178 | 178 | 166 | 151 | 141 | 155 | |
Specialty($M) | 101 | 90.2 | 51.4 | 72.2 | 55.2 | 63.3 | 57.9 | 60.4 | 51.8 | ||||
AvKARE($M) | 26.2 | 39.1 | 42.7 | 42.3 | 33.2 | 28.6 | 23.5 | 28.3 | 25.6 | 26.3 | 23.2 | 26.2 | |
14 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-06.
See a number that looks wrong?